187 related articles for article (PubMed ID: 30612984)
1. Markers of systemic involvement and death in hospitalized cancer patients with severe cutaneous adverse reactions.
Mori S; Hickey A; Dusza SW; Lacouture ME; Markova A
J Am Acad Dermatol; 2019 Mar; 80(3):608-616. PubMed ID: 30612984
[TBL] [Abstract][Full Text] [Related]
2. Association of interleukin-6 and tumor necrosis factor-α with mortality in hospitalized patients with cancer.
Stoll JR; Vaidya TS; Mori S; Dusza SW; Lacouture ME; Markova A
J Am Acad Dermatol; 2021 Feb; 84(2):273-282. PubMed ID: 32171811
[TBL] [Abstract][Full Text] [Related]
3. Occupational trichloroethylene hypersensitivity syndrome: human herpesvirus 6 reactivation and rash phenotypes.
Kamijima M; Wang H; Yamanoshita O; Ito Y; Xia L; Yanagiba Y; Chen C; Okamura A; Huang Z; Qiu X; Song X; Cai T; Liu L; Ge Y; Deng Y; Naito H; Yoshikawa T; Tohyama M; Li L; Huang H; Nakajima T
J Dermatol Sci; 2013 Dec; 72(3):218-24. PubMed ID: 23928230
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology of severe drug hypersensitivity.
Dodiuk-Gad RP; Laws PM; Shear NH
Semin Cutan Med Surg; 2014 Mar; 33(1):2-9. PubMed ID: 25037253
[TBL] [Abstract][Full Text] [Related]
5. Cicatrizing Conjunctivitis in a Patient Diagnosed With Drug Reaction With Eosinophilia and Systemic Symptoms/Drug-Induced Hypersensitivity Syndrome but With Features of Stevens-Johnson Syndrome.
Bohm KJ; Ciralsky JB; Harp JL; Bajaj S; Sippel KC
Cornea; 2016 Jun; 35(6):888-91. PubMed ID: 27078005
[TBL] [Abstract][Full Text] [Related]
6. Severe Cutaneous Adverse Drug Reactions in Pediatric Patients: A Multicenter Study.
Dibek Misirlioglu E; Guvenir H; Bahceci S; Haktanir Abul M; Can D; Usta Guc BE; Erkocoğlu M; Toyran M; Nacaroglu HT; Civelek E; Buyuktiryaki B; Ginis T; Orhan F; Kocabas CN
J Allergy Clin Immunol Pract; 2017; 5(3):757-763. PubMed ID: 28351788
[TBL] [Abstract][Full Text] [Related]
7. A retrospective study of DRESS - drug reaction with eosinophilia and systemic symptoms.
Mehrholz D; Urban AE; Herstowska M; Nowicki R; Cubała W; Barańska-Rybak W
Psychiatr Pol; 2017 Dec; 51(6):1079-1093. PubMed ID: 29432504
[TBL] [Abstract][Full Text] [Related]
8. Adverse cutaneous drug reactions in a single quaternary referral hospital.
Botelho LF; Porro AM; Enokihara MM; Tomimori J
Int J Dermatol; 2016 Apr; 55(4):e198-203. PubMed ID: 26710962
[TBL] [Abstract][Full Text] [Related]
9. Clinical features and prognostic factors in severe cutaneous drug reactions.
Yang MS; Kang MG; Jung JW; Song WJ; Kang HR; Cho SH; Min KU
Int Arch Allergy Immunol; 2013; 162(4):346-54. PubMed ID: 24193402
[TBL] [Abstract][Full Text] [Related]
10. Systemic drug reactions with skin involvement: Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS.
Darlenski R; Kazandjieva J; Tsankov N
Clin Dermatol; 2015; 33(5):538-41. PubMed ID: 26321400
[TBL] [Abstract][Full Text] [Related]
11. The serum level of HMGB1 (high mobility group box 1 protein) is preferentially high in drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms.
Fujita H; Matsukura S; Watanabe T; Komitsu N; Watanabe Y; Takahashi Y; Kambara T; Ikezawa Z; Aihara M
Br J Dermatol; 2014 Dec; 171(6):1585-8. PubMed ID: 24903194
[No Abstract] [Full Text] [Related]
12. Severe cutaneous adverse reactions in a local hospital setting: a 5-year retrospective study.
Su P; Aw CW
Int J Dermatol; 2014 Nov; 53(11):1339-45. PubMed ID: 25070588
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers for acute GVHD: can we predict the unpredictable?
Chen YB; Cutler CS
Bone Marrow Transplant; 2013 Jun; 48(6):755-60. PubMed ID: 22863728
[TBL] [Abstract][Full Text] [Related]
14. Severe cutaneous adverse reactions related to systemic antibiotics.
Lin YF; Yang CH; Sindy H; Lin JY; Rosaline Hui CY; Tsai YC; Wu TS; Huang CT; Kao KC; Hu HC; Chiu CH; Hung SI; Chung WH
Clin Infect Dis; 2014 May; 58(10):1377-85. PubMed ID: 24599767
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic markers of severe cutaneous adverse drug reactions.
Borroni RG
G Ital Dermatol Venereol; 2014 Apr; 149(2):219-26. PubMed ID: 24819643
[TBL] [Abstract][Full Text] [Related]
16. Skin-Homing IL-13-Producing T Cells Expand in the Circulation of Patients with Drug Rash with Eosinophilia and Systemic Symptoms.
Teraki Y; Fukuda T
Dermatology; 2017; 233(2-3):242-249. PubMed ID: 28601883
[TBL] [Abstract][Full Text] [Related]
17. Methylprednisolone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis: clinical evaluation and analysis of biomarkers.
Hirahara K; Kano Y; Sato Y; Horie C; Okazaki A; Ishida T; Aoyama Y; Shiohara T
J Am Acad Dermatol; 2013 Sep; 69(3):496-8. PubMed ID: 23957982
[No Abstract] [Full Text] [Related]
18. Severe cutaneous adverse reactions to drugs.
Duong TA; Valeyrie-Allanore L; Wolkenstein P; Chosidow O
Lancet; 2017 Oct; 390(10106):1996-2011. PubMed ID: 28476287
[TBL] [Abstract][Full Text] [Related]
19. A 10-years retrospective study on Severe Cutaneous Adverse Reactions (SCARs) in a tertiary hospital in Penang, Malaysia.
Loo CH; Tan WC; Khor YH; Chan LC
Med J Malaysia; 2018 Apr; 73(2):73-77. PubMed ID: 29703869
[TBL] [Abstract][Full Text] [Related]
20. Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis.
Correia O; Delgado L; Barbosa IL; Campilho F; Fleming-Torrinha J
J Am Acad Dermatol; 2002 Jul; 47(1):58-62. PubMed ID: 12077582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
